Virax Biolabs Group Limited filings document a foreign private issuer developing immunology research and diagnostic technologies, including disclosures tied to the ViraxImmune platform and immune-profiling strategy. Form 6-K reports include shareholder letters, investor presentation exhibits, clinical and commercial framework updates, and statements on the company’s ordinary shares.
The filing record also covers capital-structure matters such as private placements, pre-funded warrants, preferred investment options and ordinary-share issuance. Governance disclosures include annual general meeting notices, proxy materials, shareholder voting and quorum matters, auditor ratification, director elections, board committee appointments, equity incentive plans, and amendments to memorandum and articles of association.
Virax Biolabs Group Ltd reports an institutional beneficial ownership filing showing 9.99% of ordinary shares, equal to 823,909 shares, held by Armistice Capital, LLC and attributed to Steven Boyd as managing member, with an ownership reporting date of 12/31/2025.
The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder, and that voting and dispositive power are exercised jointly (shared power: 823,909 shares). The Master Fund is identified as the entity entitled to proceeds or dividends.
Virax Biolabs Group Limited has called its 2025 annual general meeting for March 11, 2026, in Glasgow. Shareholders are being asked to ratify Reliant CPA PC as auditor, re-appoint five current directors, approve a share consolidation, adopt updated governing documents, approve a new equity plan, and authorize potential adjournment.
The proposed share consolidation would combine between 10 and 15 existing ordinary shares into 1 share on or before July 11, 2026, with fractional shares rounded up. This is intended to help the company satisfy Nasdaq’s minimum $1.00 bid price requirement after receiving a noncompliance notice in July 2025.
The board is also seeking approval of a new 2026 Equity Incentive Plan and UK Sub-Plan reserving 2,000,000 ordinary shares for awards. Existing 2022–2024 plans cover smaller pools, much of which is already granted. The board unanimously recommends voting “FOR” all six proposals.
Virax Biolabs Group Limited has filed a resale registration covering up to 25,875,000 ordinary shares for existing investors. These shares are issuable from a December 2025 private placement and consist of 12,500,000 shares from Pre-Funded Warrants, 12,500,000 shares from Preferred Investment Options, and 875,000 shares from Placement Agent Warrants. As of December 17, 2025, Virax had 7,423,432 ordinary shares outstanding.
Virax is an emerging growth immunology-focused biotechnology company developing T cell diagnostics and immune profiling tools, including its in-development ViraxImmune™ assay and ImmuneSelect research-use-only portfolio. In the related private placement with Armistice Capital, Virax raised approximately $5,000,000 in gross proceeds and issued long-dated, low-priced warrants and options. The selling shareholders will receive all proceeds from resales, while Virax may receive additional cash only if these warrants and options are exercised.